VRXA News

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Europe SPAC Summit 2026 to Convene Leading SPAC Sponsors, Investors, and European Growth Companies in Zurich on December 10

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio

VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan